Fast Track designation highlights high unmet medical need in the treatment of Fabry disease Protalix BioTherapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pegunigalsidase alfa, or PRX-102, the Company’s plant cell-expressed recombinant, pegylated, cross-linked α-galactosidase-A candidate for the treatment of Fabry disease. The FDA’s Fast Track designation … Continue reading “Protalix BioTherapeutics’ pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration”
Read MoreMonth: February 2018

Subscribe to Our Newsletter
Please submit your email address to receive our next newsletter.
News
Archive
- October 2019
- July 2019
- June 2019
- March 2019
- December 2018
- October 2018
- August 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- July 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- August 2016
- July 2016
- June 2016
- May 2015
- September 2014
- April 2014
- December 2013
- November 2013
- March 2013
Quick links
Latest Tweets
Fabry International Network is very proud to be at SSIEM 2019! Fabry International Network - Facilitate │Support │… twitter.com/i/web/status/11695…
Workshops in progress... #1FDSM #FINexpertmeeting pic.twitter.com/aWau0S6FaV
Fabry International Network © 2013 - All rights reserved